Publications by authors named "Rossing M"

Nuclear actin polymerization was reported to control different nuclear processes, but its regulation is poorly understood. Here, we show that N-WASP can trigger the formation of nuclear N-WASP/F-actin nodules. While a cancer hotspot mutant of N-WASP lacking the VCA domain (V418fs) had a dominant negative function on nuclear F-actin, an even shorter truncation mutant found in melanoma (R128*) strongly promoted nuclear actin polymerization.

View Article and Find Full Text PDF
Article Synopsis
  • The management of advanced ovarian cancer (AOC) has improved due to molecular diagnostics that help predict how patients will respond to PARP inhibitors, particularly based on homologous recombination deficiency (HRD) status.
  • This study analyzed tumor samples from a clinical trial to investigate why HRD status isn't always a reliable indicator of sensitivity to PARP inhibitors.
  • Key findings included that some HRD-negative samples showed responses to treatment despite their status, while some HRD-positive samples did not, emphasizing the need to consider other genetic factors beyond HRD status.
View Article and Find Full Text PDF
Article Synopsis
  • Metastatic urothelial carcinoma (mUC) has a poor prognosis, and the study focuses on Prostaglandin Reductase 1 (PTGR1), which is crucial for the effectiveness of acylfulven drugs for treating specific mUC patients with ERCC2 mutations.
  • The study evaluated PTGR1 expression in untreated mUC patients using immunohistochemistry (IHC), RNA expression analysis, and targeted genomic panels to identify candidates for clinical trials and assess the potential of PTGR1 as a prognostic biomarker.
  • Results indicated that 40% of tumors tested positive for PTGR1 via IHC, demonstrating high sensitivity and specificity in RNA expression analysis, which correlated with tumor mutations and overall
View Article and Find Full Text PDF
Article Synopsis
  • Maintenance therapies like PARP inhibitors and bevacizumab have improved outcomes for advanced ovarian cancer patients, prompting a study to explore treatment variability across Europe.
  • A Delphi study was conducted with experts to understand maintenance treatment strategies and gauge consensus on best practices.
  • Key factors influencing treatment choices include tumor mutation status and perceived risk of disease progression, with high-risk cases defined by advanced FIGO stages or residual disease after initial treatment.
View Article and Find Full Text PDF
Article Synopsis
  • BDUC is a difficult-to-diagnose bleeding disorder mostly affecting women, and this study explores its connection to hypermobility disorders and vitamin C levels.
  • The study included 60 patients with BDUC, finding a significant prevalence of hypermobility traits and hyperextensible skin compared to healthy controls, along with some diagnosed with hypermobile Ehlers-Danlos syndrome.
  • Results indicated that while patients had adequate vitamin C levels, they were still lower than those in healthy controls, suggesting a potential area for further research on vitamin C supplementation for BDUC patients.
View Article and Find Full Text PDF

Background: Hereditary anemias are a group of genetic diseases prevalent worldwide and pose a significant health burden on patients and societies. The clinical phenotype of hereditary anemias varies from compensated hemolysis to life-threatening anemia. They can be roughly categorized into three broad categories: hemoglobinopathies, membranopathies, and enzymopathies.

View Article and Find Full Text PDF

Introduction: Urothelial tract cancer (UTC) ranks as the tenth most prevalent cancer and holds the seventh position in terms of mortality worldwide. Despite its prevalence and mortality ranking, there are still gaps in the knowledge of the mutational landscape in patients with advanced disease who have limited therapeutic options after multiple lines of prior treatment. This study compares the genomic and transcriptomic landscape, and targeted treatment options between metastatic UTC (mUTC) patients treated with multiple lines of therapy compared to newly diagnosed, untreated Muscle Invasive Bladder Cancer (MIBC).

View Article and Find Full Text PDF

To identify credible causal risk variants (CCVs) associated with different histotypes of epithelial ovarian cancer (EOC), we performed genome-wide association analysis for 470,825 genotyped and 10,163,797 imputed SNPs in 25,981 EOC cases and 105,724 controls of European origin. We identified five histotype-specific EOC risk regions (p value <5 × 10) and confirmed previously reported associations for 27 risk regions. Conditional analyses identified an additional 11 signals independent of the primary signal at six risk regions (p value <10).

View Article and Find Full Text PDF

Background: Primary metastatic breast cancer (pMBC) accounts for 5-10% of annual breast cancers with a median survival of 3-4 years, varying among subtypes. In Denmark, the incidence of breast cancer increased until 2010, followed by a stabilisation. Several factors influencing pMBC incidence and survival, including screening prevalence, staging methods, and classification standards, remain pivotal but inadequately documented.

View Article and Find Full Text PDF

BACKGROUNDIntrinsic molecular subtypes define distinct biological breast cancers and can be used to further improve diagnosis and risk allocation.METHODSThe Copenhagen Breast Cancer Genomics Study (CBCGS) prospectively included women diagnosed with breast cancer at Rigshospitalet from 2014 to 2021. Eligible patients were females with a primary invasive breast cancer (T1c, if N0M0; otherwise, any T, any N, or any M stage) and no prior malignancy.

View Article and Find Full Text PDF

Background: Assessment of homologous recombinant deficient (HRD) phenotypes is key for managing Poly (ADP-ribose) polymerase inhibitor (PARPi) treatment. To accommodate the need for a validated HRD platform and enhance targeted treatment of ovarian cancer patients, a Nordic core facility for the myChoice® CDx platform was established in Denmark.

Materials And Methods: Comparative calculations and statistics are based on information from test requisitions and results (Genome Instability Score [GIS], BRCA status and combined HRD status) obtained from ovarian and breast cancer samples submitted for HRD-testing by myChoice® CDx through the Nordic core facility in the 2-year period.

View Article and Find Full Text PDF

Importance: Validation of a new method for prognostication of de novo metastatic breast cancer (dnMBC) to better reflect the heterogenecity of the disease.

Objective: To perform external methodological validation of the Plichta staging system, a novel prognostic system for de novo metastatic breast cancer (dnMBC).

Design, Setting, And Participants: This retrospective cohort study used a multicenter, nationwide, population-based Danish Breast Cancer Group database to validate the new method.

View Article and Find Full Text PDF

Purpose: To meet the urgent need for accessible homologous recombination-deficient (HRD) test options, we validated a laboratory-developed test (LDT) and a functional RAD51 assay to assess patients with ovarian cancer and predict the clinical benefit of poly(ADP-ribose) polymerase inhibitor therapy.

Methods: Optimization of the LDT cutoff and validation on the basis of samples from 91 patients enrolled in the ENGOT-ov24/NSGO-AVANOVA1&2 trial (ClinicalTrials.gov identifier: NCT02354131), previously subjected to commercial CDx HRD testing (CDx).

View Article and Find Full Text PDF

Urokinase plasminogen activator receptor (uPAR) encoded by the gene is known as a clinical marker for cell invasiveness in glioblastoma multiforme (GBM). It is additionally implicated in various processes, including angiogenesis and inflammation within the tumor microenvironment. However, there has not been a comprehensive study that depicts the overall functions and molecular cooperators of with respect to intra-tumoral subtypes of GBM.

View Article and Find Full Text PDF

Background: Reports of dual carriers of pathogenic BRCA1 variants in trans are extremely rare, and so far, most individuals have been associated with a Fanconi Anemia-like phenotype.

Methods: We identified two families with a BRCA1 in-frame exon 20 duplication (Ex20dup). In one male individual, the variant was in trans with the BRCA1 frameshift variant c.

View Article and Find Full Text PDF

Molecular subtyping is essential to infer tumor aggressiveness and predict prognosis. In practice, tumor profiling requires in-depth knowledge of bioinformatics tools involved in the processing and analysis of the generated data. Additionally, data incompatibility (e.

View Article and Find Full Text PDF

Purpose: Germline pathogenic variants in CHEK2 confer moderately elevated breast cancer risk (odds ratio, OR ∼ 2.5), qualifying carriers for enhanced breast cancer screening. Besides pathogenic variants, dozens of missense CHEK2 variants of uncertain significance (VUS) have been identified, hampering the clinical utility of germline genetic testing (GGT).

View Article and Find Full Text PDF

Estrogen receptor (ER) and human epidermal growth factor 2 (HER2) expression guide the use of neoadjuvant chemotherapy (NACT) in patients with early breast cancer. We evaluate the independent predictive value of adding a multigene profile (CIT256 and PAM50) to immunohistochemical (IHC) profile regarding pathological complete response (pCR) and conversion of positive to negative axillary lymph node status. The cohort includes 458 patients who had genomic profiling performed as standard of care.

View Article and Find Full Text PDF

Background: Detection of circulating tumor-derived material (cTM) in the peripheral blood (PB) of cancer patients has been shown to be useful in early diagnosis, prediction of prognosis, and disease monitoring. However, it has not yet been thoroughly evaluated for pediatric sarcoma patients.

Methods: We searched the PubMed and EMBASE databases for studies reporting the detection of circulating tumor cells, circulating tumor DNA, and circulating RNA in PB of pediatric sarcoma patients.

View Article and Find Full Text PDF

Studies of primary hyperparathyroidism (PHPT) in multiple endocrine neoplasia type 2A (MEN 2A) shows divergence in frequency, disease definition, reporting of clinical characteristics and traces of selection bias. This is a nationwide population-based retrospective study of PHPT in MEN 2A, suggesting a representative frequency, with complete reporting and a strict PHPT definition. The Danish MEN 2A cohort 1930-2021 was used.

View Article and Find Full Text PDF

Next-generation sequencing (NGS) has raised a growing interest in phage display research. Sequencing depth is a pivotal parameter for using NGS. In the current study, we made a side-by-side comparison of two NGS platforms with different sequencing depths, denoted as lower-throughput (LTP) and higher-throughput (HTP).

View Article and Find Full Text PDF

Targeting glioblastoma (GBM) stem-like cells (GSCs) is a common interest in both the laboratory investigation and clinical treatment of GBM. Most of the currently applied GBM stem-like markers lack validation and comparison with common standards regarding their efficiency and feasibility in various targeting methods. Using single-cell RNA sequencing datasets from 37 GBM patients, we obtained a large pool of 2173 GBM stem-like marker candidates.

View Article and Find Full Text PDF

Background: Inherited platelet disorders (IPDs) are rare diseases characterized by reduced blood platelet counts and/or impaired platelet function. Recognizing IPDs is advisable but often challenging. The diagnostic tools include clinical evaluation, platelet function tests, and molecular analyses.

View Article and Find Full Text PDF

The principal presumption of phage display biopanning is that the naïve library contains an unbiased repertoire of peptides, and thus, the enriched variants derive from the affinity selection of an entirely random peptide pool. In the current study, we utilized deep sequencing to characterize the widely used Ph.DTM-12 phage display peptide library (New England Biolabs).

View Article and Find Full Text PDF